

# Mark D Long

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7717462/mark-d-long-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34  
papers

514  
citations

15  
h-index

21  
g-index

41  
ext. papers

808  
ext. citations

8.3  
avg, IF

3.96  
L-index

#	Paper	IF	Citations
34	MUC1-C Dictates JUN and BAF-mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.. <i>Molecular Cancer Research</i> , <b>2022</b> ,	6.6	2
33	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.. <i>OncoImmunology</i> , <b>2022</b> , 11, 2029298	7.2	2
32	Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers. <i>Cancers</i> , <b>2022</b> , 14, 2350	6.6	
31	Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2580	6.6	0
30	Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8 T-Cell Responses. <i>Advanced Science</i> , <b>2021</b> , e2103023	13.6	2
29	MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. <i>Oncogene</i> , <b>2021</b> , 40, 4930-4940	9.2	6
28	CD8 T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	3
27	Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 11405	4.9	2
26	MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. <i>Cancer Research</i> , <b>2021</b> , 81, 1111-1122	10.1	15
25	MUC1-C integrates activation of the IFN- $\gamma$ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer <b>2021</b> , 9,		6
24	Activation of NF- $\kappa$ B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	5
23	Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 23, 38-50	6.4	3
22	Concurrent Aspirin Use Is Associated with Improved Outcome in Rectal Cancer Patients Who Undergo Chemoradiation Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
21	Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.. <i>Cell Reports</i> , <b>2021</b> , 37, 110109	10.6	4
20	MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 338	17.4	41
19	MUC1-C drives stemness in progression of colitis to colorectal cancer. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	15
18	Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. <i>Nature Communications</i> , <b>2020</b> , 11, 52	17.4	17

17	Identification of transcription factor co-regulators that drive prostate cancer progression. <i>Scientific Reports</i> , <b>2020</b> , 10, 20332	4.9	7
16	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. <i>Nature Communications</i> , <b>2020</b> , 11, 5415	17.4	35
15	Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2147-2155	7.5	7
14	MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , <b>2019</b> , 79, 5711-5722	10.1	22
13	The miR-96 and RAR $\beta$ signaling axis governs androgen signaling and prostate cancer progression. <i>Oncogene</i> , <b>2019</b> , 38, 421-444	9.2	27
12	MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. <i>Oncogene</i> , <b>2019</b> , 38, 7266-7277	10.7	11
11	Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4682-4696	15.9	20
10	Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 173, 130-138	5.1	9
9	miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. <i>Frontiers in Bioscience - Landmark</i> , <b>2017</b> , 22, 212-229	2.8	10
8	Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF- $\kappa$ B binding that is linked to immune phenotypes. <i>BMC Genomics</i> , <b>2017</b> , 18, 132	4.5	27
7	The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. <i>Biomolecules</i> , <b>2017</b> , 7,	5.9	61
6	Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. <i>Oncotarget</i> , <b>2017</b> , 8, 103758-103774	3.3	10
5	Vitamin D receptor and RXR in the post-genomic era. <i>Journal of Cellular Physiology</i> , <b>2015</b> , 230, 758-66	7	26
4	Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 7330-48	20.1	18
3	Pan-cancer analyses of the nuclear receptor superfamily. <i>Nuclear Receptor Research</i> , <b>2015</b> , 2,	1.4	31
2	Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer. <i>Carcinogenesis</i> , <b>2014</b> , 35, 262-71	4.6	18
1	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. <i>Oncotarget</i> , <b>2014</b> , 5, 824-40	3.3	44